nodes	percent_of_prediction	percent_of_DWPC	metapath
Clofarabine—hematologic cancer—muscle cancer	0.694	1	CtDrD
Clofarabine—ABCG2—Dactinomycin—muscle cancer	0.0636	0.34	CbGbCtD
Clofarabine—ABCG2—Vincristine—muscle cancer	0.0392	0.21	CbGbCtD
Clofarabine—ABCG2—Etoposide—muscle cancer	0.0359	0.192	CbGbCtD
Clofarabine—ABCG2—Doxorubicin—muscle cancer	0.0245	0.131	CbGbCtD
Clofarabine—ABCG2—Methotrexate—muscle cancer	0.0237	0.127	CbGbCtD
Clofarabine—RRM1—larynx—muscle cancer	0.00616	0.208	CbGeAlD
Clofarabine—RRM2—embryo—muscle cancer	0.00164	0.0555	CbGeAlD
Clofarabine—RRM2—renal system—muscle cancer	0.00124	0.042	CbGeAlD
Clofarabine—RRM2—Vinorelbine—Vincristine—muscle cancer	0.00113	0.451	CbGdCrCtD
Clofarabine—POLA1—Vinblastine—Vincristine—muscle cancer	0.00107	0.426	CbGdCrCtD
Clofarabine—RRM1—smooth muscle tissue—muscle cancer	0.00107	0.0362	CbGeAlD
Clofarabine—DCK—embryo—muscle cancer	0.00106	0.0358	CbGeAlD
Clofarabine—RRM1—renal system—muscle cancer	0.00103	0.0349	CbGeAlD
Clofarabine—POLA1—tendon—muscle cancer	0.00101	0.0343	CbGeAlD
Clofarabine—POLA1—bone marrow—muscle cancer	0.000983	0.0332	CbGeAlD
Clofarabine—RRM2—tendon—muscle cancer	0.000969	0.0328	CbGeAlD
Clofarabine—POLA1—vagina—muscle cancer	0.000941	0.0318	CbGeAlD
Clofarabine—RRM2—bone marrow—muscle cancer	0.000939	0.0317	CbGeAlD
Clofarabine—RRM1—cardiac atrium—muscle cancer	0.000924	0.0312	CbGeAlD
Clofarabine—RRM2—vagina—muscle cancer	0.000899	0.0304	CbGeAlD
Clofarabine—RRM1—E2F transcription factor network—TFE3—muscle cancer	0.000864	0.127	CbGpPWpGaD
Clofarabine—POLA1—testis—muscle cancer	0.00084	0.0284	CbGeAlD
Clofarabine—RRM2—head—muscle cancer	0.000831	0.0281	CbGeAlD
Clofarabine—RRM1—tendon—muscle cancer	0.000805	0.0272	CbGeAlD
Clofarabine—RRM2—testis—muscle cancer	0.000803	0.0271	CbGeAlD
Clofarabine—RRM1—bone marrow—muscle cancer	0.00078	0.0264	CbGeAlD
Clofarabine—RRM1—vagina—muscle cancer	0.000747	0.0253	CbGeAlD
Clofarabine—DCK—cardiac atrium—muscle cancer	0.000718	0.0243	CbGeAlD
Clofarabine—RRM2—E2F transcription factor network—TFE3—muscle cancer	0.000712	0.105	CbGpPWpGaD
Clofarabine—RRM1—head—muscle cancer	0.00069	0.0233	CbGeAlD
Clofarabine—RRM1—testis—muscle cancer	0.000667	0.0225	CbGeAlD
Clofarabine—DCK—tendon—muscle cancer	0.000625	0.0211	CbGeAlD
Clofarabine—DCK—bone marrow—muscle cancer	0.000606	0.0205	CbGeAlD
Clofarabine—RRM1—E2F transcription factor network—TP73—muscle cancer	0.000584	0.086	CbGpPWpGaD
Clofarabine—DCK—vagina—muscle cancer	0.00058	0.0196	CbGeAlD
Clofarabine—DCK—head—muscle cancer	0.000536	0.0181	CbGeAlD
Clofarabine—DCK—testis—muscle cancer	0.000518	0.0175	CbGeAlD
Clofarabine—POLA1—E2F transcription factor network—TFE3—muscle cancer	0.000487	0.0717	CbGpPWpGaD
Clofarabine—RRM2—E2F transcription factor network—TP73—muscle cancer	0.000481	0.0709	CbGpPWpGaD
Clofarabine—ABCG2—bone marrow—muscle cancer	0.000338	0.0114	CbGeAlD
Clofarabine—POLA1—E2F transcription factor network—TP73—muscle cancer	0.000329	0.0485	CbGpPWpGaD
Clofarabine—ABCG2—vagina—muscle cancer	0.000324	0.0109	CbGeAlD
Clofarabine—DCK—Epirubicin—Doxorubicin—muscle cancer	0.00031	0.123	CbGdCrCtD
Clofarabine—ABCG2—testis—muscle cancer	0.000289	0.00977	CbGeAlD
Clofarabine—RRM1—Integrated Pancreatic Cancer Pathway—WT1—muscle cancer	0.000205	0.0302	CbGpPWpGaD
Clofarabine—Candida infection—Doxorubicin—muscle cancer	0.000157	0.00195	CcSEcCtD
Clofarabine—Skin exfoliation—Doxorubicin—muscle cancer	0.000157	0.00195	CcSEcCtD
Clofarabine—Oedema—Dactinomycin—muscle cancer	0.000156	0.00194	CcSEcCtD
Clofarabine—Urethral disorder—Etoposide—muscle cancer	0.000156	0.00194	CcSEcCtD
Clofarabine—Infection—Dactinomycin—muscle cancer	0.000155	0.00193	CcSEcCtD
Clofarabine—RRM1—Fluoropyrimidine Activity—TP53—muscle cancer	0.000155	0.0229	CbGpPWpGaD
Clofarabine—Leukopenia—Vincristine—muscle cancer	0.000153	0.0019	CcSEcCtD
Clofarabine—Thrombocytopenia—Dactinomycin—muscle cancer	0.000153	0.0019	CcSEcCtD
Clofarabine—Erythema multiforme—Etoposide—muscle cancer	0.000151	0.00187	CcSEcCtD
Clofarabine—RRM1—Integrated Pancreatic Cancer Pathway—BUB1B—muscle cancer	0.00015	0.0221	CbGpPWpGaD
Clofarabine—Rash maculo-papular—Doxorubicin—muscle cancer	0.000149	0.00186	CcSEcCtD
Clofarabine—Renal failure acute—Methotrexate—muscle cancer	0.000149	0.00186	CcSEcCtD
Clofarabine—Anorexia—Dactinomycin—muscle cancer	0.000149	0.00185	CcSEcCtD
Clofarabine—Mouth ulceration—Doxorubicin—muscle cancer	0.000149	0.00185	CcSEcCtD
Clofarabine—Neoplasm—Doxorubicin—muscle cancer	0.000149	0.00185	CcSEcCtD
Clofarabine—RRM1—E2F transcription factor network—CDKN2A—muscle cancer	0.000148	0.0218	CbGpPWpGaD
Clofarabine—Cardiac disorder—Etoposide—muscle cancer	0.000148	0.00184	CcSEcCtD
Clofarabine—Flushing—Etoposide—muscle cancer	0.000148	0.00184	CcSEcCtD
Clofarabine—Hypertension—Vincristine—muscle cancer	0.000148	0.00184	CcSEcCtD
Clofarabine—Pulmonary oedema—Doxorubicin—muscle cancer	0.000146	0.00182	CcSEcCtD
Clofarabine—Myalgia—Vincristine—muscle cancer	0.000146	0.00181	CcSEcCtD
Clofarabine—Angiopathy—Etoposide—muscle cancer	0.000144	0.0018	CcSEcCtD
Clofarabine—Immune system disorder—Etoposide—muscle cancer	0.000144	0.00179	CcSEcCtD
Clofarabine—Mediastinal disorder—Etoposide—muscle cancer	0.000144	0.00178	CcSEcCtD
Clofarabine—Chills—Etoposide—muscle cancer	0.000143	0.00178	CcSEcCtD
Clofarabine—Sepsis—Doxorubicin—muscle cancer	0.000143	0.00177	CcSEcCtD
Clofarabine—Musculoskeletal discomfort—Dactinomycin—muscle cancer	0.000142	0.00177	CcSEcCtD
Clofarabine—Alopecia—Etoposide—muscle cancer	0.000141	0.00175	CcSEcCtD
Clofarabine—Lethargy—Methotrexate—muscle cancer	0.000141	0.00175	CcSEcCtD
Clofarabine—Oedema—Vincristine—muscle cancer	0.00014	0.00174	CcSEcCtD
Clofarabine—Infection—Vincristine—muscle cancer	0.000139	0.00172	CcSEcCtD
Clofarabine—Nervous system disorder—Vincristine—muscle cancer	0.000137	0.0017	CcSEcCtD
Clofarabine—Thrombocytopenia—Vincristine—muscle cancer	0.000137	0.0017	CcSEcCtD
Clofarabine—Decreased appetite—Dactinomycin—muscle cancer	0.000136	0.00169	CcSEcCtD
Clofarabine—Hyperhidrosis—Vincristine—muscle cancer	0.000135	0.00168	CcSEcCtD
Clofarabine—Fatigue—Dactinomycin—muscle cancer	0.000135	0.00168	CcSEcCtD
Clofarabine—Back pain—Etoposide—muscle cancer	0.000134	0.00167	CcSEcCtD
Clofarabine—Pain—Dactinomycin—muscle cancer	0.000134	0.00166	CcSEcCtD
Clofarabine—Anorexia—Vincristine—muscle cancer	0.000133	0.00166	CcSEcCtD
Clofarabine—Irritability—Methotrexate—muscle cancer	0.000132	0.00164	CcSEcCtD
Clofarabine—Hypotension—Vincristine—muscle cancer	0.00013	0.00162	CcSEcCtD
Clofarabine—Renal failure acute—Doxorubicin—muscle cancer	0.000129	0.00161	CcSEcCtD
Clofarabine—Feeling abnormal—Dactinomycin—muscle cancer	0.000129	0.0016	CcSEcCtD
Clofarabine—Anaemia—Etoposide—muscle cancer	0.000128	0.00159	CcSEcCtD
Clofarabine—RRM2—Fluoropyrimidine Activity—TP53—muscle cancer	0.000128	0.0188	CbGpPWpGaD
Clofarabine—Gastrointestinal pain—Dactinomycin—muscle cancer	0.000128	0.00159	CcSEcCtD
Clofarabine—Musculoskeletal discomfort—Vincristine—muscle cancer	0.000127	0.00158	CcSEcCtD
Clofarabine—Paraesthesia—Vincristine—muscle cancer	0.000125	0.00156	CcSEcCtD
Clofarabine—RRM1—Retinoblastoma (RB) in Cancer—MDM2—muscle cancer	0.000125	0.0184	CbGpPWpGaD
Clofarabine—Toxic epidermal necrolysis—Methotrexate—muscle cancer	0.000124	0.00154	CcSEcCtD
Clofarabine—Leukopenia—Etoposide—muscle cancer	0.000124	0.00154	CcSEcCtD
Clofarabine—Abdominal pain—Dactinomycin—muscle cancer	0.000124	0.00154	CcSEcCtD
Clofarabine—Body temperature increased—Dactinomycin—muscle cancer	0.000124	0.00154	CcSEcCtD
Clofarabine—Lethargy—Doxorubicin—muscle cancer	0.000122	0.00151	CcSEcCtD
Clofarabine—RRM2—E2F transcription factor network—CDKN2A—muscle cancer	0.000122	0.0179	CbGpPWpGaD
Clofarabine—Decreased appetite—Vincristine—muscle cancer	0.000121	0.00151	CcSEcCtD
Clofarabine—Cough—Etoposide—muscle cancer	0.000121	0.0015	CcSEcCtD
Clofarabine—Gastrointestinal disorder—Vincristine—muscle cancer	0.000121	0.0015	CcSEcCtD
Clofarabine—Fatigue—Vincristine—muscle cancer	0.00012	0.0015	CcSEcCtD
Clofarabine—Hypertension—Etoposide—muscle cancer	0.00012	0.00149	CcSEcCtD
Clofarabine—Pain—Vincristine—muscle cancer	0.000119	0.00148	CcSEcCtD
Clofarabine—Pain in extremity—Doxorubicin—muscle cancer	0.000119	0.00148	CcSEcCtD
Clofarabine—Gastrointestinal haemorrhage—Doxorubicin—muscle cancer	0.000119	0.00148	CcSEcCtD
Clofarabine—Unspecified disorder of skin and subcutaneous tissue—Etoposide—muscle cancer	0.000117	0.00146	CcSEcCtD
Clofarabine—Pancreatitis—Methotrexate—muscle cancer	0.000117	0.00145	CcSEcCtD
Clofarabine—POLA1—Integrated Pancreatic Cancer Pathway—WT1—muscle cancer	0.000115	0.017	CbGpPWpGaD
Clofarabine—Hypersensitivity—Dactinomycin—muscle cancer	0.000115	0.00143	CcSEcCtD
Clofarabine—Gastrointestinal pain—Vincristine—muscle cancer	0.000114	0.00142	CcSEcCtD
Clofarabine—Pancytopenia—Methotrexate—muscle cancer	0.000113	0.00141	CcSEcCtD
Clofarabine—Infection—Etoposide—muscle cancer	0.000112	0.0014	CcSEcCtD
Clofarabine—Asthenia—Dactinomycin—muscle cancer	0.000112	0.00139	CcSEcCtD
Clofarabine—Blood creatinine increased—Doxorubicin—muscle cancer	0.000112	0.00139	CcSEcCtD
Clofarabine—Neutropenia—Methotrexate—muscle cancer	0.000111	0.00139	CcSEcCtD
Clofarabine—Dehydration—Doxorubicin—muscle cancer	0.000111	0.00138	CcSEcCtD
Clofarabine—Thrombocytopenia—Etoposide—muscle cancer	0.000111	0.00138	CcSEcCtD
Clofarabine—Upper respiratory tract infection—Methotrexate—muscle cancer	0.000111	0.00138	CcSEcCtD
Clofarabine—Tachycardia—Etoposide—muscle cancer	0.00011	0.00137	CcSEcCtD
Clofarabine—Body temperature increased—Vincristine—muscle cancer	0.00011	0.00137	CcSEcCtD
Clofarabine—Abdominal pain—Vincristine—muscle cancer	0.00011	0.00137	CcSEcCtD
Clofarabine—Skin disorder—Etoposide—muscle cancer	0.00011	0.00137	CcSEcCtD
Clofarabine—Dry skin—Doxorubicin—muscle cancer	0.000109	0.00136	CcSEcCtD
Clofarabine—Hyperhidrosis—Etoposide—muscle cancer	0.000109	0.00136	CcSEcCtD
Clofarabine—Abdominal pain upper—Doxorubicin—muscle cancer	0.000109	0.00136	CcSEcCtD
Clofarabine—Anorexia—Etoposide—muscle cancer	0.000108	0.00134	CcSEcCtD
Clofarabine—Toxic epidermal necrolysis—Doxorubicin—muscle cancer	0.000108	0.00134	CcSEcCtD
Clofarabine—Aspartate aminotransferase increased—Doxorubicin—muscle cancer	0.000108	0.00134	CcSEcCtD
Clofarabine—Diarrhoea—Dactinomycin—muscle cancer	0.000107	0.00133	CcSEcCtD
Clofarabine—Pneumonia—Methotrexate—muscle cancer	0.000107	0.00133	CcSEcCtD
Clofarabine—Infestation NOS—Methotrexate—muscle cancer	0.000106	0.00132	CcSEcCtD
Clofarabine—Infestation—Methotrexate—muscle cancer	0.000106	0.00132	CcSEcCtD
Clofarabine—Hypotension—Etoposide—muscle cancer	0.000106	0.00131	CcSEcCtD
Clofarabine—Stevens-Johnson syndrome—Methotrexate—muscle cancer	0.000105	0.00131	CcSEcCtD
Clofarabine—Alanine aminotransferase increased—Doxorubicin—muscle cancer	0.000105	0.00131	CcSEcCtD
Clofarabine—Renal failure—Methotrexate—muscle cancer	0.000104	0.0013	CcSEcCtD
Clofarabine—Stomatitis—Methotrexate—muscle cancer	0.000104	0.00129	CcSEcCtD
Clofarabine—Influenza—Doxorubicin—muscle cancer	0.000103	0.00128	CcSEcCtD
Clofarabine—Hypersensitivity—Vincristine—muscle cancer	0.000103	0.00128	CcSEcCtD
Clofarabine—RRM2—Retinoblastoma (RB) in Cancer—MDM2—muscle cancer	0.000103	0.0151	CbGpPWpGaD
Clofarabine—Paraesthesia—Etoposide—muscle cancer	0.000102	0.00126	CcSEcCtD
Clofarabine—Haematuria—Methotrexate—muscle cancer	0.000101	0.00126	CcSEcCtD
Clofarabine—Pancreatitis—Doxorubicin—muscle cancer	0.000101	0.00126	CcSEcCtD
Clofarabine—Dyspnoea—Etoposide—muscle cancer	0.000101	0.00125	CcSEcCtD
Clofarabine—Somnolence—Etoposide—muscle cancer	0.000101	0.00125	CcSEcCtD
Clofarabine—Hepatobiliary disease—Methotrexate—muscle cancer	0.0001	0.00125	CcSEcCtD
Clofarabine—Epistaxis—Methotrexate—muscle cancer	0.0001	0.00125	CcSEcCtD
Clofarabine—Asthenia—Vincristine—muscle cancer	0.0001	0.00125	CcSEcCtD
Clofarabine—Vomiting—Dactinomycin—muscle cancer	9.94e-05	0.00124	CcSEcCtD
Clofarabine—Rash—Dactinomycin—muscle cancer	9.86e-05	0.00123	CcSEcCtD
Clofarabine—Decreased appetite—Etoposide—muscle cancer	9.83e-05	0.00122	CcSEcCtD
Clofarabine—Pancytopenia—Doxorubicin—muscle cancer	9.8e-05	0.00122	CcSEcCtD
Clofarabine—Gastrointestinal disorder—Etoposide—muscle cancer	9.77e-05	0.00121	CcSEcCtD
Clofarabine—Fatigue—Etoposide—muscle cancer	9.75e-05	0.00121	CcSEcCtD
Clofarabine—Pain—Etoposide—muscle cancer	9.67e-05	0.0012	CcSEcCtD
Clofarabine—Neutropenia—Doxorubicin—muscle cancer	9.65e-05	0.0012	CcSEcCtD
Clofarabine—Upper respiratory tract infection—Doxorubicin—muscle cancer	9.59e-05	0.00119	CcSEcCtD
Clofarabine—DCK—Retinoblastoma (RB) in Cancer—MDM2—muscle cancer	9.59e-05	0.0141	CbGpPWpGaD
Clofarabine—Haemoglobin—Methotrexate—muscle cancer	9.59e-05	0.00119	CcSEcCtD
Clofarabine—Diarrhoea—Vincristine—muscle cancer	9.56e-05	0.00119	CcSEcCtD
Clofarabine—Haemorrhage—Methotrexate—muscle cancer	9.54e-05	0.00119	CcSEcCtD
Clofarabine—Urinary tract disorder—Methotrexate—muscle cancer	9.42e-05	0.00117	CcSEcCtD
Clofarabine—Urethral disorder—Methotrexate—muscle cancer	9.35e-05	0.00116	CcSEcCtD
Clofarabine—Weight decreased—Doxorubicin—muscle cancer	9.34e-05	0.00116	CcSEcCtD
Clofarabine—Feeling abnormal—Etoposide—muscle cancer	9.32e-05	0.00116	CcSEcCtD
Clofarabine—Nausea—Dactinomycin—muscle cancer	9.28e-05	0.00115	CcSEcCtD
Clofarabine—Pneumonia—Doxorubicin—muscle cancer	9.25e-05	0.00115	CcSEcCtD
Clofarabine—Gastrointestinal pain—Etoposide—muscle cancer	9.25e-05	0.00115	CcSEcCtD
Clofarabine—Dizziness—Vincristine—muscle cancer	9.24e-05	0.00115	CcSEcCtD
Clofarabine—Infestation NOS—Doxorubicin—muscle cancer	9.2e-05	0.00114	CcSEcCtD
Clofarabine—Infestation—Doxorubicin—muscle cancer	9.2e-05	0.00114	CcSEcCtD
Clofarabine—Stevens-Johnson syndrome—Doxorubicin—muscle cancer	9.12e-05	0.00113	CcSEcCtD
Clofarabine—Renal failure—Doxorubicin—muscle cancer	9.04e-05	0.00112	CcSEcCtD
Clofarabine—Erythema multiforme—Methotrexate—muscle cancer	9.02e-05	0.00112	CcSEcCtD
Clofarabine—Neuropathy peripheral—Doxorubicin—muscle cancer	9.02e-05	0.00112	CcSEcCtD
Clofarabine—Stomatitis—Doxorubicin—muscle cancer	8.97e-05	0.00111	CcSEcCtD
Clofarabine—Jaundice—Doxorubicin—muscle cancer	8.97e-05	0.00111	CcSEcCtD
Clofarabine—Abdominal pain—Etoposide—muscle cancer	8.94e-05	0.00111	CcSEcCtD
Clofarabine—Body temperature increased—Etoposide—muscle cancer	8.94e-05	0.00111	CcSEcCtD
Clofarabine—Vomiting—Vincristine—muscle cancer	8.88e-05	0.0011	CcSEcCtD
Clofarabine—Cardiac disorder—Methotrexate—muscle cancer	8.85e-05	0.0011	CcSEcCtD
Clofarabine—Rash—Vincristine—muscle cancer	8.81e-05	0.00109	CcSEcCtD
Clofarabine—Dermatitis—Vincristine—muscle cancer	8.8e-05	0.00109	CcSEcCtD
Clofarabine—Haematuria—Doxorubicin—muscle cancer	8.77e-05	0.00109	CcSEcCtD
Clofarabine—Headache—Vincristine—muscle cancer	8.75e-05	0.00109	CcSEcCtD
Clofarabine—Hepatobiliary disease—Doxorubicin—muscle cancer	8.7e-05	0.00108	CcSEcCtD
Clofarabine—Epistaxis—Doxorubicin—muscle cancer	8.68e-05	0.00108	CcSEcCtD
Clofarabine—Angiopathy—Methotrexate—muscle cancer	8.65e-05	0.00108	CcSEcCtD
Clofarabine—Sinusitis—Doxorubicin—muscle cancer	8.63e-05	0.00107	CcSEcCtD
Clofarabine—Immune system disorder—Methotrexate—muscle cancer	8.62e-05	0.00107	CcSEcCtD
Clofarabine—Mediastinal disorder—Methotrexate—muscle cancer	8.6e-05	0.00107	CcSEcCtD
Clofarabine—Chills—Methotrexate—muscle cancer	8.56e-05	0.00106	CcSEcCtD
Clofarabine—POLA1—Integrated Pancreatic Cancer Pathway—BUB1B—muscle cancer	8.44e-05	0.0124	CbGpPWpGaD
Clofarabine—Alopecia—Methotrexate—muscle cancer	8.43e-05	0.00105	CcSEcCtD
Clofarabine—Mental disorder—Methotrexate—muscle cancer	8.36e-05	0.00104	CcSEcCtD
Clofarabine—Hypersensitivity—Etoposide—muscle cancer	8.33e-05	0.00104	CcSEcCtD
Clofarabine—POLA1—E2F transcription factor network—CDKN2A—muscle cancer	8.33e-05	0.0123	CbGpPWpGaD
Clofarabine—Malnutrition—Methotrexate—muscle cancer	8.3e-05	0.00103	CcSEcCtD
Clofarabine—Erythema—Methotrexate—muscle cancer	8.3e-05	0.00103	CcSEcCtD
Clofarabine—Haemoglobin—Doxorubicin—muscle cancer	8.3e-05	0.00103	CcSEcCtD
Clofarabine—Nausea—Vincristine—muscle cancer	8.3e-05	0.00103	CcSEcCtD
Clofarabine—Haemorrhage—Doxorubicin—muscle cancer	8.26e-05	0.00103	CcSEcCtD
Clofarabine—Urinary tract disorder—Doxorubicin—muscle cancer	8.16e-05	0.00101	CcSEcCtD
Clofarabine—Oedema peripheral—Doxorubicin—muscle cancer	8.14e-05	0.00101	CcSEcCtD
Clofarabine—Asthenia—Etoposide—muscle cancer	8.12e-05	0.00101	CcSEcCtD
Clofarabine—Connective tissue disorder—Doxorubicin—muscle cancer	8.12e-05	0.00101	CcSEcCtD
Clofarabine—Urethral disorder—Doxorubicin—muscle cancer	8.1e-05	0.00101	CcSEcCtD
Clofarabine—Back pain—Methotrexate—muscle cancer	8.03e-05	0.000999	CcSEcCtD
Clofarabine—Pruritus—Etoposide—muscle cancer	8e-05	0.000995	CcSEcCtD
Clofarabine—Erythema multiforme—Doxorubicin—muscle cancer	7.81e-05	0.000971	CcSEcCtD
Clofarabine—Diarrhoea—Etoposide—muscle cancer	7.74e-05	0.000962	CcSEcCtD
Clofarabine—ABCG2—Imatinib Resistance in Chronic Myeloid Leukemia—KIT—muscle cancer	7.71e-05	0.0114	CbGpPWpGaD
Clofarabine—Anaemia—Methotrexate—muscle cancer	7.67e-05	0.000954	CcSEcCtD
Clofarabine—Cardiac disorder—Doxorubicin—muscle cancer	7.66e-05	0.000953	CcSEcCtD
Clofarabine—Flushing—Doxorubicin—muscle cancer	7.66e-05	0.000953	CcSEcCtD
Clofarabine—Angiopathy—Doxorubicin—muscle cancer	7.49e-05	0.000932	CcSEcCtD
Clofarabine—Dizziness—Etoposide—muscle cancer	7.48e-05	0.00093	CcSEcCtD
Clofarabine—Immune system disorder—Doxorubicin—muscle cancer	7.46e-05	0.000927	CcSEcCtD
Clofarabine—RRM2—Mitotic G1-G1/S phases—CDKN2A—muscle cancer	7.44e-05	0.011	CbGpPWpGaD
Clofarabine—Mediastinal disorder—Doxorubicin—muscle cancer	7.44e-05	0.000925	CcSEcCtD
Clofarabine—Leukopenia—Methotrexate—muscle cancer	7.43e-05	0.000924	CcSEcCtD
Clofarabine—Chills—Doxorubicin—muscle cancer	7.41e-05	0.000921	CcSEcCtD
Clofarabine—Alopecia—Doxorubicin—muscle cancer	7.3e-05	0.000907	CcSEcCtD
Clofarabine—Cough—Methotrexate—muscle cancer	7.25e-05	0.000901	CcSEcCtD
Clofarabine—Mental disorder—Doxorubicin—muscle cancer	7.24e-05	0.0009	CcSEcCtD
Clofarabine—Vomiting—Etoposide—muscle cancer	7.19e-05	0.000894	CcSEcCtD
Clofarabine—Erythema—Doxorubicin—muscle cancer	7.19e-05	0.000894	CcSEcCtD
Clofarabine—Malnutrition—Doxorubicin—muscle cancer	7.19e-05	0.000894	CcSEcCtD
Clofarabine—RRM1—Retinoblastoma (RB) in Cancer—TP53—muscle cancer	7.15e-05	0.0105	CbGpPWpGaD
Clofarabine—Rash—Etoposide—muscle cancer	7.13e-05	0.000887	CcSEcCtD
Clofarabine—Dermatitis—Etoposide—muscle cancer	7.13e-05	0.000886	CcSEcCtD
Clofarabine—Headache—Etoposide—muscle cancer	7.09e-05	0.000881	CcSEcCtD
Clofarabine—Myalgia—Methotrexate—muscle cancer	7.07e-05	0.000879	CcSEcCtD
Clofarabine—Arthralgia—Methotrexate—muscle cancer	7.07e-05	0.000879	CcSEcCtD
Clofarabine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—muscle cancer	7.02e-05	0.000873	CcSEcCtD
Clofarabine—POLA1—Retinoblastoma (RB) in Cancer—MDM2—muscle cancer	7.02e-05	0.0103	CbGpPWpGaD
Clofarabine—Back pain—Doxorubicin—muscle cancer	6.95e-05	0.000865	CcSEcCtD
Clofarabine—Infection—Methotrexate—muscle cancer	6.73e-05	0.000837	CcSEcCtD
Clofarabine—Nausea—Etoposide—muscle cancer	6.72e-05	0.000835	CcSEcCtD
Clofarabine—Nervous system disorder—Methotrexate—muscle cancer	6.65e-05	0.000826	CcSEcCtD
Clofarabine—Anaemia—Doxorubicin—muscle cancer	6.65e-05	0.000826	CcSEcCtD
Clofarabine—RRM1—Integrated Pancreatic Cancer Pathway—MDM2—muscle cancer	6.64e-05	0.00979	CbGpPWpGaD
Clofarabine—RRM1—Metabolism—FH—muscle cancer	6.64e-05	0.00978	CbGpPWpGaD
Clofarabine—Thrombocytopenia—Methotrexate—muscle cancer	6.63e-05	0.000825	CcSEcCtD
Clofarabine—Agitation—Doxorubicin—muscle cancer	6.61e-05	0.000821	CcSEcCtD
Clofarabine—Skin disorder—Methotrexate—muscle cancer	6.58e-05	0.000818	CcSEcCtD
Clofarabine—Hyperhidrosis—Methotrexate—muscle cancer	6.55e-05	0.000814	CcSEcCtD
Clofarabine—Anorexia—Methotrexate—muscle cancer	6.46e-05	0.000803	CcSEcCtD
Clofarabine—Leukopenia—Doxorubicin—muscle cancer	6.44e-05	0.0008	CcSEcCtD
Clofarabine—RRM1—Integrated Pancreatic Cancer Pathway—PTGS2—muscle cancer	6.4e-05	0.00944	CbGpPWpGaD
Clofarabine—Hypotension—Methotrexate—muscle cancer	6.33e-05	0.000787	CcSEcCtD
Clofarabine—Cough—Doxorubicin—muscle cancer	6.27e-05	0.00078	CcSEcCtD
Clofarabine—Hypertension—Doxorubicin—muscle cancer	6.21e-05	0.000772	CcSEcCtD
Clofarabine—ABCG2—HIF-2-alpha transcription factor network—VEGFA—muscle cancer	6.18e-05	0.00911	CbGpPWpGaD
Clofarabine—Musculoskeletal discomfort—Methotrexate—muscle cancer	6.17e-05	0.000768	CcSEcCtD
Clofarabine—Arthralgia—Doxorubicin—muscle cancer	6.12e-05	0.000761	CcSEcCtD
Clofarabine—Myalgia—Doxorubicin—muscle cancer	6.12e-05	0.000761	CcSEcCtD
Clofarabine—Anxiety—Doxorubicin—muscle cancer	6.1e-05	0.000758	CcSEcCtD
Clofarabine—Paraesthesia—Methotrexate—muscle cancer	6.08e-05	0.000756	CcSEcCtD
Clofarabine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—muscle cancer	6.08e-05	0.000756	CcSEcCtD
Clofarabine—Dyspnoea—Methotrexate—muscle cancer	6.04e-05	0.000751	CcSEcCtD
Clofarabine—Somnolence—Methotrexate—muscle cancer	6.02e-05	0.000749	CcSEcCtD
Clofarabine—RRM2—Cell Cycle, Mitotic—BUB1B—muscle cancer	5.98e-05	0.0088	CbGpPWpGaD
Clofarabine—Decreased appetite—Methotrexate—muscle cancer	5.89e-05	0.000732	CcSEcCtD
Clofarabine—RRM2—Retinoblastoma (RB) in Cancer—TP53—muscle cancer	5.89e-05	0.00868	CbGpPWpGaD
Clofarabine—Oedema—Doxorubicin—muscle cancer	5.87e-05	0.000729	CcSEcCtD
Clofarabine—Gastrointestinal disorder—Methotrexate—muscle cancer	5.85e-05	0.000727	CcSEcCtD
Clofarabine—Fatigue—Methotrexate—muscle cancer	5.84e-05	0.000726	CcSEcCtD
Clofarabine—Infection—Doxorubicin—muscle cancer	5.83e-05	0.000725	CcSEcCtD
Clofarabine—Pain—Methotrexate—muscle cancer	5.79e-05	0.00072	CcSEcCtD
Clofarabine—Nervous system disorder—Doxorubicin—muscle cancer	5.75e-05	0.000715	CcSEcCtD
Clofarabine—Thrombocytopenia—Doxorubicin—muscle cancer	5.75e-05	0.000714	CcSEcCtD
Clofarabine—Tachycardia—Doxorubicin—muscle cancer	5.73e-05	0.000712	CcSEcCtD
Clofarabine—Skin disorder—Doxorubicin—muscle cancer	5.7e-05	0.000709	CcSEcCtD
Clofarabine—Hyperhidrosis—Doxorubicin—muscle cancer	5.67e-05	0.000705	CcSEcCtD
Clofarabine—Anorexia—Doxorubicin—muscle cancer	5.59e-05	0.000695	CcSEcCtD
Clofarabine—Feeling abnormal—Methotrexate—muscle cancer	5.58e-05	0.000694	CcSEcCtD
Clofarabine—Gastrointestinal pain—Methotrexate—muscle cancer	5.54e-05	0.000689	CcSEcCtD
Clofarabine—DCK—Retinoblastoma (RB) in Cancer—TP53—muscle cancer	5.5e-05	0.00811	CbGpPWpGaD
Clofarabine—Hypotension—Doxorubicin—muscle cancer	5.48e-05	0.000682	CcSEcCtD
Clofarabine—RRM2—Metabolism—FH—muscle cancer	5.47e-05	0.00805	CbGpPWpGaD
Clofarabine—POLA1—Mitotic M-M/G1 phases—BUB1B—muscle cancer	5.46e-05	0.00805	CbGpPWpGaD
Clofarabine—Body temperature increased—Methotrexate—muscle cancer	5.36e-05	0.000666	CcSEcCtD
Clofarabine—Abdominal pain—Methotrexate—muscle cancer	5.36e-05	0.000666	CcSEcCtD
Clofarabine—Musculoskeletal discomfort—Doxorubicin—muscle cancer	5.35e-05	0.000665	CcSEcCtD
Clofarabine—RRM2—Cell Cycle—BUB1B—muscle cancer	5.34e-05	0.00787	CbGpPWpGaD
Clofarabine—Paraesthesia—Doxorubicin—muscle cancer	5.27e-05	0.000655	CcSEcCtD
Clofarabine—Dyspnoea—Doxorubicin—muscle cancer	5.23e-05	0.00065	CcSEcCtD
Clofarabine—Somnolence—Doxorubicin—muscle cancer	5.22e-05	0.000649	CcSEcCtD
Clofarabine—DCK—Metabolism—FH—muscle cancer	5.11e-05	0.00753	CbGpPWpGaD
Clofarabine—Decreased appetite—Doxorubicin—muscle cancer	5.1e-05	0.000634	CcSEcCtD
Clofarabine—POLA1—Mitotic G1-G1/S phases—CDKN2A—muscle cancer	5.09e-05	0.0075	CbGpPWpGaD
Clofarabine—Gastrointestinal disorder—Doxorubicin—muscle cancer	5.07e-05	0.00063	CcSEcCtD
Clofarabine—Fatigue—Doxorubicin—muscle cancer	5.06e-05	0.000629	CcSEcCtD
Clofarabine—RRM1—Integrated Pancreatic Cancer Pathway—VEGFA—muscle cancer	5.04e-05	0.00743	CbGpPWpGaD
Clofarabine—Pain—Doxorubicin—muscle cancer	5.02e-05	0.000624	CcSEcCtD
Clofarabine—Hypersensitivity—Methotrexate—muscle cancer	4.99e-05	0.000621	CcSEcCtD
Clofarabine—Asthenia—Methotrexate—muscle cancer	4.86e-05	0.000604	CcSEcCtD
Clofarabine—Feeling abnormal—Doxorubicin—muscle cancer	4.84e-05	0.000601	CcSEcCtD
Clofarabine—Gastrointestinal pain—Doxorubicin—muscle cancer	4.8e-05	0.000597	CcSEcCtD
Clofarabine—Pruritus—Methotrexate—muscle cancer	4.79e-05	0.000596	CcSEcCtD
Clofarabine—ABCG2—Fluoropyrimidine Activity—TP53—muscle cancer	4.78e-05	0.00705	CbGpPWpGaD
Clofarabine—Body temperature increased—Doxorubicin—muscle cancer	4.64e-05	0.000577	CcSEcCtD
Clofarabine—Abdominal pain—Doxorubicin—muscle cancer	4.64e-05	0.000577	CcSEcCtD
Clofarabine—Diarrhoea—Methotrexate—muscle cancer	4.64e-05	0.000576	CcSEcCtD
Clofarabine—Dizziness—Methotrexate—muscle cancer	4.48e-05	0.000557	CcSEcCtD
Clofarabine—Hypersensitivity—Doxorubicin—muscle cancer	4.32e-05	0.000537	CcSEcCtD
Clofarabine—Vomiting—Methotrexate—muscle cancer	4.31e-05	0.000536	CcSEcCtD
Clofarabine—Rash—Methotrexate—muscle cancer	4.27e-05	0.000531	CcSEcCtD
Clofarabine—Dermatitis—Methotrexate—muscle cancer	4.27e-05	0.000531	CcSEcCtD
Clofarabine—Headache—Methotrexate—muscle cancer	4.25e-05	0.000528	CcSEcCtD
Clofarabine—Asthenia—Doxorubicin—muscle cancer	4.21e-05	0.000523	CcSEcCtD
Clofarabine—Pruritus—Doxorubicin—muscle cancer	4.15e-05	0.000516	CcSEcCtD
Clofarabine—POLA1—Cell Cycle, Mitotic—BUB1B—muscle cancer	4.09e-05	0.00602	CbGpPWpGaD
Clofarabine—POLA1—Retinoblastoma (RB) in Cancer—TP53—muscle cancer	4.03e-05	0.00593	CbGpPWpGaD
Clofarabine—Nausea—Methotrexate—muscle cancer	4.03e-05	0.0005	CcSEcCtD
Clofarabine—Diarrhoea—Doxorubicin—muscle cancer	4.01e-05	0.000499	CcSEcCtD
Clofarabine—Dizziness—Doxorubicin—muscle cancer	3.88e-05	0.000482	CcSEcCtD
Clofarabine—RRM1—Integrated Pancreatic Cancer Pathway—TP53—muscle cancer	3.81e-05	0.00562	CbGpPWpGaD
Clofarabine—RRM1—Metabolism—MED12—muscle cancer	3.75e-05	0.00553	CbGpPWpGaD
Clofarabine—POLA1—Integrated Pancreatic Cancer Pathway—MDM2—muscle cancer	3.74e-05	0.00551	CbGpPWpGaD
Clofarabine—Vomiting—Doxorubicin—muscle cancer	3.73e-05	0.000464	CcSEcCtD
Clofarabine—Rash—Doxorubicin—muscle cancer	3.7e-05	0.00046	CcSEcCtD
Clofarabine—Dermatitis—Doxorubicin—muscle cancer	3.7e-05	0.00046	CcSEcCtD
Clofarabine—Headache—Doxorubicin—muscle cancer	3.68e-05	0.000457	CcSEcCtD
Clofarabine—POLA1—Cell Cycle—BUB1B—muscle cancer	3.65e-05	0.00538	CbGpPWpGaD
Clofarabine—ABCG2—HIF-1-alpha transcription factor network—VEGFA—muscle cancer	3.63e-05	0.00536	CbGpPWpGaD
Clofarabine—POLA1—Integrated Pancreatic Cancer Pathway—PTGS2—muscle cancer	3.61e-05	0.00532	CbGpPWpGaD
Clofarabine—Nausea—Doxorubicin—muscle cancer	3.49e-05	0.000433	CcSEcCtD
Clofarabine—RRM1—Metabolism—ENO2—muscle cancer	3.42e-05	0.00504	CbGpPWpGaD
Clofarabine—RRM2—Metabolism—MED12—muscle cancer	3.09e-05	0.00455	CbGpPWpGaD
Clofarabine—DCK—Metabolism—MED12—muscle cancer	2.89e-05	0.00425	CbGpPWpGaD
Clofarabine—POLA1—Integrated Pancreatic Cancer Pathway—VEGFA—muscle cancer	2.84e-05	0.00419	CbGpPWpGaD
Clofarabine—RRM2—Metabolism—ENO2—muscle cancer	2.82e-05	0.00415	CbGpPWpGaD
Clofarabine—RRM2—Cell Cycle, Mitotic—CDKN2A—muscle cancer	2.73e-05	0.00402	CbGpPWpGaD
Clofarabine—DCK—Metabolism—ENO2—muscle cancer	2.63e-05	0.00388	CbGpPWpGaD
Clofarabine—RRM2—Cell Cycle—CDKN2A—muscle cancer	2.44e-05	0.0036	CbGpPWpGaD
Clofarabine—RRM2—Cell Cycle—MDM2—muscle cancer	2.37e-05	0.00349	CbGpPWpGaD
Clofarabine—POLA1—Integrated Pancreatic Cancer Pathway—TP53—muscle cancer	2.15e-05	0.00316	CbGpPWpGaD
Clofarabine—ABCG2—Metabolism—FH—muscle cancer	2.04e-05	0.00301	CbGpPWpGaD
Clofarabine—POLA1—Cell Cycle, Mitotic—CDKN2A—muscle cancer	1.87e-05	0.00275	CbGpPWpGaD
Clofarabine—POLA1—Cell Cycle—CDKN2A—muscle cancer	1.67e-05	0.00246	CbGpPWpGaD
Clofarabine—POLA1—Cell Cycle—MDM2—muscle cancer	1.62e-05	0.00239	CbGpPWpGaD
Clofarabine—RRM2—Cell Cycle—TP53—muscle cancer	1.36e-05	0.002	CbGpPWpGaD
Clofarabine—RRM1—Metabolism—PTGS2—muscle cancer	1.19e-05	0.00175	CbGpPWpGaD
Clofarabine—ABCG2—Metabolism—MED12—muscle cancer	1.15e-05	0.0017	CbGpPWpGaD
Clofarabine—ABCG2—Metabolism—ENO2—muscle cancer	1.05e-05	0.00155	CbGpPWpGaD
Clofarabine—RRM2—Metabolism—PTGS2—muscle cancer	9.81e-06	0.00145	CbGpPWpGaD
Clofarabine—POLA1—Cell Cycle—TP53—muscle cancer	9.29e-06	0.00137	CbGpPWpGaD
Clofarabine—DCK—Metabolism—PTGS2—muscle cancer	9.16e-06	0.00135	CbGpPWpGaD
Clofarabine—ABCG2—Metabolism—PTGS2—muscle cancer	3.67e-06	0.00054	CbGpPWpGaD
